Margaret M. Tarpey

Corporate Officer/Principal at University of Pittsburgh

Consumer Services

Health Technology

Profile

Margaret M.
Tarpey is the founder of Complexa, Inc. (founded in 2008).
She is currently a Professor at the University of Pittsburgh (since 2013).
Dr. Tarpey's education includes an undergraduate degree from the University of California, Riverside and a graduate degree from the University of California San Diego.

Margaret M. Tarpey active positions

Companies	Position	Start
University of Pittsburgh	Corporate Officer/Principal	-

All active positions of Margaret M. Tarpey

Former positions of Margaret M. Tarpey

Companies	Position	End
Complexa, Inc. Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA.	Founder	-

See the detail of Margaret M. Tarpey's experience

Training of Margaret M. Tarpey

University of California, Riverside	Undergraduate Degree
University of California San Diego	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Margaret M. Tarpey's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Complexa, Inc. Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA.	Health Technology